Thymosin Alpha-1 vs TB-500: A Structural and Regulatory Comparison

Introduction

Thymosin alpha-1 and TB-500 are routinely confused because both carry the thymosin name and both trace to the same research program, the calf-thymus fractionation work begun by Abraham White and Allan L. Goldstein in the 1960s. The resemblance ends there. Thymosin alpha-1 is a 28-residue peptide cleaved from the precursor protein prothymosin alpha, and its synthetic form, thymalfasin, is an approved pharmaceutical in dozens of countries outside the United States. TB-500 is a synthetic seven-residue fragment of thymosin beta-4, a separate 43-residue protein whose principal described function is sequestration of monomeric actin, and it has never been approved anywhere. This article compares the two compounds by structure, origin, pharmacological class, and regulatory record, reporting what investigators and regulators have published without drawing conclusions about either compound's suitability for any purpose. Research-grade thymosin alpha-1 and TB-500 reference materials are cataloged with per-batch certificates of analysis.

Thymosin Alpha-1: A Prothymosin-Derived Acidic Peptide

The thymosin story begins with a 1966 paper by Goldstein, Slater, and White in the Proceedings of the National Academy of Sciences, which described the preparation and partial purification of a thymic lymphocytopoietic factor the authors named thymosin [1]. Over the following decade the Goldstein laboratory resolved the partially purified preparation known as thymosin fraction 5 into discrete peptides, designating them by Greek letters according to electrophoretic mobility [1, 7]. In 1977, Goldstein, Low, McAdoo, and colleagues reported the complete sequence of thymosin alpha-1: a 28-residue, heat-stable, highly acidic peptide bearing an N-terminal acetyl group [2]. Low and colleagues published the accompanying isolation and characterization data in the Journal of Biological Chemistry in 1979 [3].

The peptide's biosynthetic origin was clarified in 1984, when Haritos, Goodall, and Horecker isolated prothymosin alpha from rat thymus and identified it as the major immunoreactive form of thymosin alpha-1, establishing that the 28-residue peptide is the N-terminal segment of a larger precursor protein rather than an independently encoded product [4]. The sequence, Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn, has a molecular weight of approximately 3,108 daltons and an isoelectric point near pH 4.2. A 2011 NMR study by Elizondo-Riojas and colleagues reported that the peptide is largely unstructured in water but adopts a helical segment in a membrane-mimicking environment [5].

Mechanistic work by Romani and colleagues, published in Blood in 2006, reframed the peptide's pharmacology around Toll-like receptor signaling in dendritic cells, reporting activation of dendritic-cell tryptophan catabolism in murine models [6]. That framing has become the dominant paradigm in the post-2006 literature and is discussed in the thymosin alpha-1 research overview.

Findings from research models do not establish safety or efficacy in humans. Sparta Labs makes no claims about the use of this compound.

The synthetic form, thymalfasin (Zadaxin), was developed by SciClone Pharmaceuticals and reviewed as an investigational drug by Billich in 2002 [8]. Dominari and colleagues' 2020 review in the World Journal of Virology summarized its regulatory footprint: approval in more than 30 countries, with hepatitis B as the primary indication, alongside multiple FDA orphan-drug designations but no FDA marketing authorization [7]. In 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed thymosin alpha-1 among bulk substances nominated for the section 503B list [9]. The full regulatory timeline is covered in the thymosin alpha-1 history article.

TB-500: A Synthetic Fragment of Thymosin Beta-4

Thymosin beta-4 was also resolved from thymosin fraction 5, but it is the product of a different gene. Low, Hu, and Goldstein reported its complete 43-residue sequence in the Proceedings of the National Academy of Sciences in 1981, initially describing it as a thymic hormone that induced terminal deoxynucleotidyl transferase activity in thymocyte populations [10]. The thymic framing did not survive long. Hannappel and colleagues reported in 1982 that thymosin beta-4 was present at high concentration in spleen, brain, lung, liver, and peritoneal macrophages of rats and mice, a distribution inconsistent with an organ-specific hormone [11]. In 1991, Safer, Elzinga, and Nachmias demonstrated that thymosin beta-4 was indistinguishable from Fx, an actin-sequestering peptide isolated independently from platelets, and that it bound monomeric G-actin in a one-to-one complex that blocked polymerization [12].

Fragment-mapping followed. Hannappel and Wartenberg reported in 1993, using a DNase I inhibition assay, that actin-sequestering activity was concentrated in the central region of the sequence and was reduced or lost in shorter fragments and in related beta-thymosins with altered central residues [13]. The crystallographic basis for the interaction was published by Irobi and colleagues in EMBO Journal in 2004, who described how the beta-thymosin module contacts actin across both the barbed and pointed end faces of the monomer, with the LKKTET motif engaging the hydrophobic cleft [14]. Philp and colleagues reported in 2003 that a synthetic peptide containing the central actin-binding site reproduced part of the parent protein's activity in chorioallantoic membrane and cell-culture assays [15].

TB-500 as a named compound entered the literature through anti-doping analytical chemistry rather than through a clinical program. Esposito, Deventer, Goeman, Van der Eycken, and Van Eenoo synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, in Drug Testing and Analysis in 2012, identifying it as the material found in a product sold under the TB-500 name [16]. The heptapeptide has a molecular weight of approximately 839 daltons, against 4,921 daltons for the parent protein.

The regulatory record belongs to the parent protein, not the fragment. Goldstein, Hannappel, Sosne, and Kleinman's 2012 review summarized RegeneRx Biopharmaceuticals' clinical programs with full-length thymosin beta-4 in ophthalmic (RGN-259) and non-ophthalmic (RGN-352) formulations [17]. No IND or controlled clinical trial has been associated with Ac-LKKTETQ itself. The World Anti-Doping Agency lists thymosin beta-4 and its derivatives, including TB-500, under section S2 of the Prohibited List as growth factor modulators [18]. Additional context is available in the TB-500 research overview and the TB-500 history.

Structural Comparison

• Parent protein. Thymosin alpha-1 is the N-terminal 28 residues of prothymosin alpha, released by post-translational processing [4]. TB-500 is a synthetic copy of residues 17 to 23 of thymosin beta-4, a distinct 43-residue protein encoded by a separate gene [10, 16]. The two parents share the thymosin name only because both were isolated from the same calf-thymus fraction.
• Length and mass. Thymosin alpha-1: 28 residues, approximately 3,108 daltons. TB-500: seven residues, approximately 839 daltons [2, 16].
• Charge and composition. Thymosin alpha-1 is highly acidic, with nine glutamate or aspartate residues against four lysines and an isoelectric point near pH 4.2 [2]. Ac-LKKTETQ carries two lysines against one glutamate and is net basic, a composition consistent with the electrostatic contacts described at the thymosin beta-4/actin interface [14].
• N-terminal acetylation. Both peptides are N-acetylated. In thymosin alpha-1 the acetyl group is native to the processed peptide [2]. In TB-500 it is a synthetic cap that mirrors the acetylated N-terminus of the full-length parent [16].
• Secondary structure. Thymosin alpha-1 is reported to be largely disordered in water with a helical segment that forms in membrane-mimicking conditions [5]. Beta-thymosins are intrinsically disordered and fold only on binding actin; the seven-residue fragment retains the central motif but not the flanking helices of the parent [14].
• Molecular target described in the literature. Thymosin alpha-1: Toll-like receptor pathway signaling in dendritic cells [6]. Thymosin beta-4 and its central fragment: direct binding to monomeric G-actin [12, 14].
• Regulatory status. Thymosin alpha-1: approved as thymalfasin (Zadaxin) in more than 30 countries; FDA orphan designations without FDA marketing approval; 2024 PCAC review [7, 9]. TB-500: never approved; WADA S2 [16, 18].

Pharmacological Class Context

The two compounds occupy different pharmacological classes despite the shared name. Thymosin alpha-1 is grouped in the literature with thymic immunomodulatory peptides and, since the Romani papers, more specifically as a Toll-like receptor pathway modulator [6, 7]. Its class neighbors are other thymus-derived and thymus-mimetic peptides rather than cytoskeletal ligands. Thymosin beta-4 and its fragments belong to the beta-thymosin family of actin-monomer-sequestering proteins, a family whose defining biochemical property is one-to-one G-actin binding [12, 14]. Regulators reflect the same distinction: thymalfasin appears in national drug registers, while thymosin beta-4 and its derivatives appear on the WADA Prohibited List as growth factor modulators [18].

Within the Sparta Labs research library, TB-500 is more often compared with gastric-origin peptides in the tissue-repair research cluster, as in the BPC-157 vs TB-500 comparison, than with thymosin alpha-1. The two thymosins were never tested head-to-head in a published controlled study, and this article makes no comparative efficacy statement about either compound.

Research-grade thymosin alpha-1 and TB-500 sold by chemical suppliers are laboratory reference materials, not pharmaceutical products, and are strictly for research use only. The existence of approved thymalfasin products in other jurisdictions does not extend any approval to research-grade material.

References

1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966;56(3):1010-1017. PMID: 5230555. PubMed
2. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-729. PMID: 265536. PMC392366
3. Low TL, Thurman GB, McAdoo M, McClure J, Rossio JL, Naylor PH, Goldstein AL. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem. 1979;254(3):981-986. PMID: 216684. PubMed
4. Haritos AA, Goodall GJ, Horecker BL. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci USA. 1984;81(4):1008-1011. PMID: 6583693. DOI: 10.1073/pnas.81.4.1008
5. Elizondo-Riojas MA, Chamow SM, Tuthill CW, Gorenstein DG, Volk DE. NMR structure of human thymosin alpha-1. Biochem Biophys Res Commun. 2011;416(3-4):356-361. PMID: 22115779. DOI: 10.1016/j.bbrc.2011.11.041
6. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. PMID: 16741252. DOI: 10.1182/blood-2006-02-004762
7. Dominari A, Hathaway D 3rd, Pandav K, Vasan S, Dhindsa DS, Dave K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID: 33362999. PMC7747025
8. Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs. 2002;3(5):698-707. PMID: 12090542. PubMed
9. US Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting: Thymosin Alpha-1 Related Bulk Drug Substances. FDA Briefing Document. 2024. FDA
10. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133. PubMed
11. Hannappel E, Xu GJ, Morgan J, Hempstead J, Horecker BL. Thymosin beta 4: a ubiquitous peptide in rat and mouse tissues. Proc Natl Acad Sci USA. 1982;79(7):2172-2175. PMID: 6954532. DOI: 10.1073/pnas.79.7.2172
12. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID: 1999398. PubMed
13. Hannappel E, Wartenberg F. Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay. Biol Chem Hoppe Seyler. 1993;374(2):117-122. PMID: 8471179. DOI: 10.1515/bchm3.1993.374.1-6.117
14. Irobi E, Aguda AH, Larsson M, Guerin C, Yin HL, Burtnick LD, Blanchoin L, Robinson RC. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. PMID: 15329672. DOI: 10.1038/sj.emboj.7600372
15. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PMID: 14500546. DOI: 10.1096/fj.03-0121fje
16. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. PMID: 22962027. DOI: 10.1002/dta.1402
17. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294. DOI: 10.1517/14712598.2012.634793
18. World Anti-Doping Agency. The Prohibited List. Montreal: WADA. WADA Prohibited List